A tool for predicting overall survival in patients with Ewing sarcoma: a multicenter retrospective study

Abstract

Objective The aim of this study was to establish and validate a clinical prediction model for assessing the risk of metastasis and patient survival in Ewing's sarcoma (ES). Methods Patients diagnosed with ES from the Surveillance, Epidemiology and End Results (SEER) database for the period 2010-2016 were extracted, and the data after exclusion of vacant terms was used as the training set (n=767). Prediction models predicting patients' overall survival (OS) at 1 and 3 years were created by cox regression analysis and visualized using Nomogram and web calculator. Multicenter data from four medical institutions were used as the validation set (n=51), and the model consistency was verified using calibration plots, and receiver operating characteristic (ROC) verified the predictive ability of the model. Finally, a clinical decision curve was used to demonstrate the clinical utility of the model. Results The results of multivariate cox regression showed that age, , bone metastasis, tumor size, and chemotherapy were independent prognostic factors of ES patients. Internal and external validation results: calibration plots showed that the model had a good agreement for patient survival at 1 and 3 years; ROC showed that it possessed a good predictive ability and clinical decision curve proved that it possessed good clinical utility. Conclusions The tool built in this paper to predict 1- and 3-year survival in ES patients (https://drwenleli0910.shinyapps.io/EwingApp/) has a good identification and predictive power.

Serum glutathione peroxidase 4 as a novel biomarker for nontraumatic osteonecrosis of the femoral head: A retrospective case-control study

“…The predictive accuracy may be improved by a nomogram including size, location of osteonecrosis and GPx4 levels in future study. [25,26] Finally, ROC curve analysis was performed to test the efficacy of serum GPx4 in the diagnosis and progression prediction of NONFH. The AUC of ROC was 0.808 for serum GPx4 in the diagnosis of NONFH and 0.847 in the prediction of collapse of the femoral head.…”

Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer

“…Single-cell sequencing analysis was performed to find differential glutamine metabolism-related genes among individual BC cells. Using the Cox risk model and LASSO regression, new risk profiles were constructed based on the expression levels of genes related to glutamine metabolism in the TCGA-BC dataset (24). In addition, in breast cancer, glutamine metabolic profiles can be used to identify changes in immune infiltration and immune checkpoints.…”

Exploration of Flavonoids as Lead Compounds against Ewing Sarcoma through Molecular Docking, Pharmacogenomics Analysis, and Molecular Dynamics Simulations

“…Ewing sarcoma (ES) is the second-most common primary bone tumor that is highly malignant and has a peak incidence in the second decade of life [ 1 ]. It affects 2.6 and 2.8 children per million in the United States and Germany, respectively [ 2 ].…”

“…ES typically develops in the femur, shoulder blades, ribs, and pelvic area [ 3 ]. Previous research has found that tumors most commonly arise in the tubular bones of the extremities (46%), mostly in the lower extremities, followed by the pelvis (25%), trunk comprising ribs and spinal trunk (22%), and other locations (6%) [ 1 ]. The 5-year overall survival (OS) rate for patients with localized ES has grown to 65%, due to the use of surgery, chemotherapy, and radiation [ 4 ].…”